ReviewRheumatology international2025
Erythroderma as a presenting feature of dermatomyositis: case-based review.
Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythroderma is an extensive, scaly erythema, involving more than 90% of the body surface area, and may be life-threatening. Dermatomyositis (DM) has been reported as a rare aetiology for erythroderma. However, the erythroderma itself would potentially mask the pathognomonic cutaneous lesions like the confluent erythema, heliotrope rash, and Gottron's sign of DM, leading to diagnostic dilemmas and potential delay in diagnosis. Here, we report a 23-year-old female with DM who had initially presented with erythroderma. Her cutaneous manifestations preceded the onset of clinical muscle weakness. She was successfully treated with systemic corticosteroids and azathioprine and is in clinical remission at 18 months follow-up. We review the literature for similar cases and found that there have been less than ten cases of erythroderma in dermatomyositis reported to date. This review enables us to explore this rare manifestation of DM. We discuss the presentation, clinical approach and decision-making in such cases.
Indexed as
Identifiers
40613922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.